4//SEC Filing
Wright Richard Chester 4
Accession 0001192482-21-000614
CIK 0001716947other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 6:08 PM ET
Size
14.0 KB
Accession
0001192482-21-000614
Insider Transaction Report
Form 4
Wright Richard Chester
Chief Business Officer
Transactions
- Award
Stock Option
2021-06-30+65,850→ 65,850 totalExercise: $1.83Exp: 2026-11-01→ Common Stock (65,850 underlying) - Award
Stock Option
2021-06-30+19,755→ 19,755 totalExercise: $2.59Exp: 2028-10-01→ Common Stock (19,755 underlying) - Award
Stock Option
2021-06-30+49,975→ 49,975 totalExercise: $3.21Exp: 2023-12-21→ Common Stock (49,975 underlying) - Award
Stock Option
2021-06-30+263,400→ 263,400 totalExercise: $1.83Exp: 2027-07-01→ Common Stock (263,400 underlying) - Award
Stock Option
2021-06-30+987,750→ 987,750 totalExercise: $2.59Exp: 2029-02-28→ Common Stock (987,750 underlying)
Footnotes (1)
- [F1]On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.
Documents
Issuer
Ensysce Biosciences, Inc.
CIK 0001716947
Entity typeother
Related Parties
1- filerCIK 0001869634
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 6:08 PM ET
- Size
- 14.0 KB